NEW YORK (360Dx) – Swedish diagnostic developer Immunovia today announced it has received a SEK4.9 million ($585,000) follow-on grant to support development studies for its Immray PanCan-d blood-based test for the early detection of pancreatic cancer.
The grant is from the Swelife Accelerator Innovation Program, which is designed to support Sweden's small-to-medium-sized enterprises. The Create Health Translational Cancer Center at Lund University will collaborate with Immunovia on its studies.
Immray PanCan-d uses antibody microarray technology and a biomarker signature to provide a rapid, robust, and accurate method for the early detection of pancreatic cancer, Immunovia said. Last December, the company announced the start of a multicenter prospective validation study for the test based on the analysis of 1,000 people at high risk for familial pancreatic cancer.
"We now have the confidence to accelerate our activities to move into the commercialization program also for diabetes and early symptoms risk groups, which this grant will support," Immunovia CEO Mats Grahn said in a statement.
Last week, the company announced a collaboration with Linköping University to discover autoimmune disease diagnostic biomarkers.